Type 2 diabetes: one disease, multiple cardiovascular risk factors

被引:51
作者
Calles-Escandon, J [1 ]
Garcia-Rubi, E [1 ]
Mirza, S [1 ]
Mortensen, A [1 ]
机构
[1] Univ Vermont, Dept Internal Med, Sect Endocrinol Diabet & Metab, Burlington, VT 05405 USA
关键词
vascular disease; diabetes; risk factors; insulin resistance;
D O I
10.1097/00019501-199901000-00004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes mellitus is a major independent risk factor for coronary artery disease. Atherosclerosis accounts for about 80% of all deaths from type 2 diabetes, of which roughly 75% ate attributable to coronary artery disease and the remainder to cerebrovascular or peripheral vascular events [1], The earlier onset and accelerated course of atherosclerosis in individuals with type 2 diabetes mellitus is multifactorial. Type 2 diabetes is associated with abnormalities in lipoprotein metabolism and increased propensity for oxidative damage. The hyperglycemia of patients with type 2 diabetes, in itself, may accelerate vascular damage. Type 2 diabetes is a hypercoagulable state attributable to enhanced coagulation and decreased fibrinolysis, as well as platelet hyperaggregability and endothelial dysfunction, Hypertension is common in individuals with type 2 diabetes and has a major impact in the accelerated atherosclerosis of this disease. This review provides an overview of selected aspects of these alterations. Coronary Artery Dis 10:23-30 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:23 / 30
页数:8
相关论文
共 102 条
[1]  
ALESSI MC, 1988, THROMB HAEMOSTASIS, V60, P491
[2]   Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease [J].
Alessi, MC ;
Peiretti, F ;
Morange, P ;
Henry, M ;
Nalbone, G ;
JuhanVague, I .
DIABETES, 1997, 46 (05) :860-867
[3]  
Baron AD, 1997, CIRCULATION, V96, P725
[4]   INTRAPLATELET SEROTONIN IN PATIENTS WITH DIABETES-MELLITUS AND PERIPHERAL VASCULAR-DISEASE [J].
BARRADAS, MA ;
GILL, DS ;
FONSECA, VA ;
MIKHAILIDIS, DP ;
DANDONA, P .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1988, 18 (04) :399-404
[5]   DECREASED PLATELET PHOSPHOINOSITIDE TURNOVER AND ENHANCED PLATELET ACTIVATION IN IDDM [J].
BASTYR, EJ ;
KADROFSKE, MM ;
DERSHIMER, RC ;
VINIK, AI .
DIABETES, 1989, 38 (09) :1097-1102
[6]   NONENZYMATIC GLYCOSYLATION PRODUCTS ON COLLAGEN COVALENTLY TRAP LOW-DENSITY LIPOPROTEIN [J].
BROWNLEE, M ;
VLASSARA, H ;
CERAMI, A .
DIABETES, 1985, 34 (09) :938-941
[7]   INHIBITION OF HEPARIN-CATALYZED HUMAN ANTITHROMBIN III ACTIVITY BY NONENZYMATIC GLYCOSYLATION - POSSIBLE ROLE IN FIBRIN DEPOSITION IN DIABETES [J].
BROWNLEE, M ;
VLASSARA, H ;
CERAMI, A .
DIABETES, 1984, 33 (06) :532-535
[8]   LIPID ADVANCED GLYCOSYLATION - PATHWAY FOR LIPID OXIDATION IN-VIVO [J].
BUCALA, R ;
MAKITA, Z ;
KOSCHINSKY, T ;
CERAMI, A ;
VLASSARA, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (14) :6434-6438
[9]  
CAGLIERO E, 1991, J BIOL CHEM, V266, P14244
[10]   Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction [J].
CallesEscandon, J ;
Ballor, D ;
HarveyBerino, J ;
Ades, P ;
Tracy, R ;
Sobel, B .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1996, 64 (01) :7-11